DOI: http://dx.doi.org/10.18203/2349-2902.isj20215147

D-dimer as a safe, convenient and easily available biomarker, when combined with conventional sentinel node biopsy in clinically node negative breast cancer to assess metastatic disease in axilla and reduce false negative results

Karan Dharamsi, Juthikaa Deherkar, Ankita Agarwal, Mrunal Ketkar

Abstract


Background: Breast cancer is frequently associated with activation of the hemostatic system and the extent of this activation correlates with a more advanced tumor stage. D-dimer is a biomarker that indicates the activation of hemostasis and fibrinolysis.

Methods: This is a prospective, observational, analytical study in which we compare plasma D-dimer levels among three groups’ i.e., healthy subjects, benign patients and breast cancer patients. We have also evaluated plasma D-dimer levels in patients with lymphadenopathy and in those patients who did not have palpable lymph nodes. Plasma D-dimer levels were further characterized based on TNM classification in breast cancer patients where quantitative D-dimer levels were correlated with clinical stage grouping.

Results: Through our study we have observed that D-dimer level is inexpensive and a convenient method for diagnosis and prognosis of breast cancer. We have used a control group so as to evaluate a more accurate result. Comparison between benign and malignant lesions was made and we have achieved a significant p value, which proved our study positive for raised D-dimer levels in cancer breast.

Conclusions: D-dimer proves to be a safe, convenient and easily available biomarker which can be combined with conventional sentinel node biopsy in clinically node negative breast cancer to assess metastatic disease in axilla and reduce false negative results. Plasma D-dimer level was positively correlated with clinical stage of solid cancers.


Keywords


D-dimer, Breast cancer, Biomarkers, Diagnostic marker, Randomized control trial, Metastasis

Full Text:

PDF

References


Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol/oncol clin N Am. 1996;10(2):457-84.

Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer. 2003;97(12):3044-52.

Oya M, Akiyama Y, Okuyama T. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jap j clin oncol. 2001;31(8):388-94.

Blackwell K, Haroon Z, Broadwater G. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J clin oncol. 2000;18(3):600-8.

Von Tempelhoff GF, Heilmann L, Hommel G. Correspondence re: N. C. Denko and A. J. Giaccia, tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res. 2001;61:795-8.

Mitter CG, Zielinski CC. Plasma levels ofd-Dimer: a crosslinked fibrin-degradation product in female breast cancer. J Cancer Res Clin Oncol. 1991;117(3):259-62.

Falanga A, Levine MN, Consonni R. The Effect of Very-low-dose Warfarin on Markers of Hypercoagulation in Metastatic Breast Cancer: Results from a Randomized Trial. Thrombosis Haemostasis. 1998;79(1):23-7.

Batschauer APB, Figueiredo CP, Bueno EC. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010;21(6):1267-72.

Von Tempelhoff GF, Dietrich M, Hommel G. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol. 1996;14(9):2560-8.

Neises M, Schafer T, Strittmatter HJ. D-dimer and plasminogen activator of the urokinase type: personal experiences with breast cancer. Geburtshilfe Frauenheilkd. 1993;53(7):455-60.

Blackwell K, Haroon Z, Broadwater G. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J clin oncol. 2000;18(3):600-8.

Kim BK, Lee JW, Park PJ. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res. 2009;11(2):R22.

Dirix LY, Salgado R, Weytjens R. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86(3):389-95.

Khangarot SS, Gupta N, Goswami B. Correlation of D dimer and factor VIII levels with histopathology in patients with breast carcinoma. Cancer Biomark. 2010;7(6):305-14.

Liu L, Zhang X, Yan B. Elevated plasma D-dimer levels correlate with long term survival of gastric cancer patients. PloS one. 2014;9(3):e90547.